Significance of Metabolites in Bioequivalence: Losartan Potassium as a Case Study
- 1 June 2014
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (6) , 1584-1591
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Conference Report: Bio-International 2005Journal of Pharmaceutical Sciences, 2007
- Biowaiver Monographs for Immediate Release Solid OralDosage Forms: PrednisoloneJournal of Pharmaceutical Sciences, 2007
- Metabolites and BioequivalenceClinical Pharmacokinetics, 2004
- Clinical Pharmacokinetics of MifepristoneClinical Pharmacokinetics, 1997
- EXP3174: The Major Active Metabolite of LosartanCardiovascular Drug Reviews, 1997
- Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.British Journal of Clinical Pharmacology, 1993
- Dose-Response Relationships of RU 486Annals of Medicine, 1993
- Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.Circulation, 1991
- Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X.Hypertension, 1990
- Potentiation by inhibition of drug degradation : 6-substituted purines and xanthine oxidaseBiochemical Pharmacology, 1963